108 related articles for article (PubMed ID: 3540867)
1. Implementation of an RIL-2/LAK cell clinical trial: a nursing perspective.
Corey BS; Collins JL
Oncol Nurs Forum; 1986; 13(6):31-6. PubMed ID: 3540867
[No Abstract] [Full Text] [Related]
2. Clinical trials with IL-2.
Seipp CA; Simpson C; Rosenberg SA
Oncol Nurs Forum; 1986; 13(6):25-9. PubMed ID: 3540866
[No Abstract] [Full Text] [Related]
3. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant melanoma with interleukin-2.
Philip PA; Flaherty L
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin 2].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1203-7. PubMed ID: 3495239
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
10. [Treatment of malignant tumors by interleukin 2 and LAK cells].
Degos L
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):119-22. PubMed ID: 3260373
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacological research with interleukin-2: implications for nursing.
Shelton BK
Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):8-13. PubMed ID: 8210794
[No Abstract] [Full Text] [Related]
12. Interleukin-2: an overview.
Jassak PF; Sticklin LA
Oncol Nurs Forum; 1986; 13(6):17-22. PubMed ID: 3540865
[No Abstract] [Full Text] [Related]
13. Alteration in body image for the patient undergoing RIL-2/LAK cell therapy.
Becker K; Koutlas J
Oncol Nurs Forum; 1990; 17(6):965. PubMed ID: 2263529
[No Abstract] [Full Text] [Related]
14. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
15. Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis.
Talmadge JE
Prog Clin Biol Res; 1986; 212():197-215. PubMed ID: 3520577
[No Abstract] [Full Text] [Related]
16. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
17. Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.
Sznol M; Dutcher JP; Atkins MB; Rayner AR; Margolin KA; Gaynor ER; Weiss GR; Aronson F; Parkinson DR; Hawkins MJ
Cancer Treat Rev; 1989 Jun; 16 Suppl A():29-38. PubMed ID: 2670213
[No Abstract] [Full Text] [Related]
18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
19. Possible association of interleukin-2 treatment with depression and suicide.
Baron DA; Hardie T; Baron SH
J Am Osteopath Assoc; 1993 Jul; 93(7):799-800. PubMed ID: 8365929
[TBL] [Abstract][Full Text] [Related]
20. Nursing guidelines and discharge planning for patients receiving recombinant interleukin-2.
Caliendo G; Joyce D; Altmiller MC
Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):25-31. PubMed ID: 8210791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
